Nebenwirkungen · Yervoy
YERVOY 5 mg/ml concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 26–27
HOS-124848 · Präparat HOS-095945
26 Combination with nivolumab (with or without chemotherapy) Blood and lymphatic system disorders Very anaemiab,i, thrombocytopaeniab, leucopoeniab, lymphopaeniab, neutropaeniab common Common eosinophilia Uncommon febrile neutropaenia Not known haemophagocytic lymphohistiocytosis Immune system disorders Common infusion-related reaction (including cytokine release syndrome), hypersensitivity Rare sarcoidosis Not known solid organ transplant rejectionf Endocrine disorders Very hypothyroidism common Common hyperthyroidism, thyroiditis, adrenal insufficiency, hypophysitis, hypopituitarism, diabetes mellitus Uncommon diabetic ketoacidosis Rare hypoparathyroidism Metabolism and nutrition disorders Very decreased appetite, hyperglycaemiab, hypoglycaemiab common Common dehydration, hypoalbuminaemia, hypophosphataemia, weight decreased Uncommon metabolic acidosis Not known tumour lysis syndromeg Nervous system disorders Very headache common Common dizziness, peripheral neuropathy Uncommon polyneuropathy, peroneal nerve palsy, autoimmune neuropathy (including facial and abducens nerve paresis), encephalitis, myasthenia gravis, Myocarditis-Myositis-Myasthenia Gravis Overlap Syndromek Rare Guillain-Barré syndrome, neuritis, myelitis (including transverse myelitis) Eye disorders Common blurred vision, dry eye Uncommon uveitis, episcleritis Rare Vogt-Koyanagi-Harada syndrome, serous retinal detachment Cardiac disorders Common tachycardia, atrial fibrillation Uncommon myocarditisa, arrhythmia (including ventricular arrhythmia)a, bradycardia Not known pericardial disordersh Vascular disorders Common hypertension Respiratory, thoracic and mediastinal disorders Very cough, dyspnoea common Common pneumonitisa, pulmonary embolisma, pleural effusion
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-06-24T11:43:00Z · SHA-256 dc5bb68a862953e5ba79b604f2ed30802a58dc667192871f56f119ed5e95af4f · Passage d70874c7d6980f6080209b2893f21492a34c45b55076756d839a80a08e02047c · Zeichen 13260–15235 im Abschnitt